Literature DB >> 20392616

Serum ferritin levels are associated with vascular damage in patients with nonalcoholic fatty liver disease.

L Valenti1, D W Swinkels, L Burdick, P Dongiovanni, H Tjalsma, B M Motta, C Bertelli, E Fatta, D Bignamini, R Rametta, S Fargion, A L Fracanzani.   

Abstract

BACKGROUND AND AIMS: Increased ferritin and body iron stores are frequently observed in nonalcoholic fatty liver disease (NAFLD), associated with heightened susceptibility to vascular damage. Conflicting data have been reported on the role of iron in atherosclerosis, with recent data suggesting that excess iron induces vascular damage by increasing levels of the hormone hepcidin, which would determine iron trapping into macrophages, oxidative stress, and promotion of transformation into foam cells. Aim of this study was to investigate the relationship between iron status and cardiovascular damage in NAFLD. METHODS AND
RESULTS: Vascular damage was evaluated by common carotid arteries intima-media thickness (CC-IMT) measurement and plaque detection by ecocolor-doppler ultrasonography in 506 patients with clinical and ultrasonographic diagnosis of NAFLD, hemochromatosis gene (HFE) mutations by restriction analysis in 342 patients. Serum hepcidin-25 was measured by time-of-flight mass spectrometry in 143 patients. At multivariate analysis CC-IMT was associated with systolic blood pressure, glucose, LDL cholesterol, abdominal circumference, age, and ferritin (p=0.048). Carotid plaques were independently associated with age, ferritin, glucose, and hypertension. Ferritin reflected iron stores and metabolic syndrome components, but not inflammation or liver damage. Hyperferritinemia was associated with increased vascular damage only in patients with HFE genotypes associated with hepcidin upregulation by iron stores (p<0.0001), and serum hepcidin-25 was independently associated with carotid plaques (p=0.05).
CONCLUSION: Ferritin levels, reflecting iron stores, are independent predictors of vascular damage in NAFLD. The mechanism may involve upregulation of hepcidin by increased iron stores in patients not carrying HFE mutations, and iron compartmentalization into macrophages.
Copyright © 2010 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20392616     DOI: 10.1016/j.numecd.2010.01.003

Source DB:  PubMed          Journal:  Nutr Metab Cardiovasc Dis        ISSN: 0939-4753            Impact factor:   4.222


  33 in total

1.  Serum ferritin is an independent predictor of histologic severity and advanced fibrosis in patients with nonalcoholic fatty liver disease.

Authors:  Kris V Kowdley; Patricia Belt; Laura A Wilson; Matthew M Yeh; Brent A Neuschwander-Tetri; Naga Chalasani; Arun J Sanyal; James E Nelson
Journal:  Hepatology       Date:  2011-12-06       Impact factor: 17.425

Review 2.  Hepcidin and HFE protein: Iron metabolism as a target for the anemia of chronic kidney disease.

Authors:  Elena Canavesi; Carlo Alfieri; Serena Pelusi; Luca Valenti
Journal:  World J Nephrol       Date:  2012-12-06

3.  Disordered vascular compliance in haemochromatosis.

Authors:  W J Cash; S O'Neill; M E O'Donnell; D R McCance; I S Young; J McEneny; I S Cadden; Neil I McDougall; M E Callender
Journal:  Ir J Med Sci       Date:  2013-09-03       Impact factor: 1.568

4.  Lower serum hepcidin and greater parenchymal iron in nonalcoholic fatty liver disease patients with C282Y HFE mutations.

Authors:  James E Nelson; Elizabeth M Brunt; Kris V Kowdley
Journal:  Hepatology       Date:  2012-09-20       Impact factor: 17.425

Review 5.  Diagnostic and therapeutic implications of the association between ferritin level and severity of nonalcoholic fatty liver disease.

Authors:  Luca Valenti; Paola Dongiovanni; Silvia Fargion
Journal:  World J Gastroenterol       Date:  2012-08-07       Impact factor: 5.742

Review 6.  The role of hepcidin and iron homeostasis in atherosclerosis.

Authors:  Florian Wunderer; Lisa Traeger; Haakon H Sigurslid; Patrick Meybohm; Donald B Bloch; Rajeev Malhotra
Journal:  Pharmacol Res       Date:  2020-01-25       Impact factor: 7.658

7.  The interplay among iron metabolism, endothelium and inflammatory cascade in dysmetabolic disorders.

Authors:  Z A Yegin; Ö T İyidir; C Demirtaş; E Suyanı; İ Yetkin; H Paşaoğlu; Ç İlhan; G T Sucak
Journal:  J Endocrinol Invest       Date:  2014-09-23       Impact factor: 4.256

Review 8.  Nonalcoholic fatty liver disease and vascular disease: state-of-the-art.

Authors:  Silvia Fargion; Marianna Porzio; Anna Ludovica Fracanzani
Journal:  World J Gastroenterol       Date:  2014-10-07       Impact factor: 5.742

Review 9.  Towards a unifying, systems biology understanding of large-scale cellular death and destruction caused by poorly liganded iron: Parkinson's, Huntington's, Alzheimer's, prions, bactericides, chemical toxicology and others as examples.

Authors:  Douglas B Kell
Journal:  Arch Toxicol       Date:  2010-08-17       Impact factor: 5.153

10.  Characterization of hepatocellular carcinoma related genes and metabolites in human nonalcoholic fatty liver disease.

Authors:  John D Clarke; Petr Novak; April D Lake; Petia Shipkova; Nelly Aranibar; Donald Robertson; Paul L Severson; Michael D Reily; Bernard W Futscher; Lois D Lehman-McKeeman; Nathan J Cherrington
Journal:  Dig Dis Sci       Date:  2013-09-19       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.